Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ther­a­pies in re­pur­posed drugs

Cal­i­for­nia-based Vaxart has dosed the first pa­tient in a Phase I study of its Covid-19 can­di­date.

The oral can­di­date, VXA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.